

Massimo Morfini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/748968/publications.pdf>

Version: 2024-02-01

61
papers

2,224
citations

218677

26
h-index

223800

46
g-index

61
all docs

61
docs citations

61
times ranked

1225
citing authors

#	ARTICLE	IF	CITATIONS
1	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2022, 122, 715-725.	3.4	9
2	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 69-81.	3.8	9
3	Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 733.	2.4	3
4	Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long-term experience at a single Haemophilia centre. <i>Haemophilia</i> , 2021, 27, e93-e101.	2.1	12
5	Practical considerations for nonfactor replacement therapies in the treatment of haemophilia with inhibitors. <i>Haemophilia</i> , 2021, 27, 340-350.	2.1	15
6	Recent Advances in the Treatment of Hemophilia: A Review. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 221-235.	3.2	21
7	Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 153, 105485.	4.0	1
8	Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trial. <i>Data in Brief</i> , 2020, 32, 106164.	1.0	1
9	The availability of new drugs for hemophilia treatment. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 721-738.	3.1	5
10	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and Siset. <i>Blood Transfusion</i> , 2020, 18, 143-151.	0.4	22
11	Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. <i>Expert Review of Hematology</i> , 2019, 12, 883-892.	2.2	2
12	Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. <i>Haemophilia</i> , 2019, 25, e364-e367.	2.1	2
13	Safety of recombinant coagulation factors in treating hemophilia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 75-85.	2.4	12
14	Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1288-1296.	3.8	15
15	Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1085-1096.	3.8	34
16	<p>Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 233-240.	1.8	11
17	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. <i>European Journal of Haematology</i> , 2019, 102, 111-122.	2.2	78
18	Practical aspects of extended half-life products for the treatment of haemophilia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 295-308.	2.5	85

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 149-162.	2.5	11
20	A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a. <i>Blood</i> , 2018, 132, 2480-2480.	1.4	1
21	Outcome measures for adult and pediatric hemophilia patients with inhibitors. <i>European Journal of Haematology</i> , 2017, 99, 103-111.	2.2	8
22	Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1023-1030.	3.4	36
23	The History of Clotting Factor Concentrates Pharmacokinetics. <i>Journal of Clinical Medicine</i> , 2017, 6, 35.	2.4	11
24	Correlation between <sc>FIX</sc> genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. <i>Haemophilia</i> , 2016, 22, 537-542.	2.1	17
25	Pain and pain management in haemophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 845-854.	1.0	66
26	Comparative pharmacokinetics of <sc>rVIII</sc>â€SingleChain and octocog alfa (Advate^{Â®}) in patients with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, 730-738.	2.1	52
27	Emerging drugs for the treatment of hemophilia A and B. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 301-313.	2.4	14
28	Population pharmacokinetics of a new longâ€acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2132-2140.	3.8	18
29	Switching treatments in haemophilia: is there a risk of inhibitor development?. <i>European Journal of Haematology</i> , 2015, 94, 284-289.	2.2	21
30	Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage. <i>European Journal of Haematology</i> , 2014, 92, 256-262.	2.2	34
31	Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. <i>Blood Transfusion</i> , 2014, 12, 314-9.	0.4	46
32	Intra-articular injections of hyaluronic acid induce positive clinical effects in knees of patients affected by haemophilic arthropathy. <i>Knee</i> , 2013, 20, 36-39.	1.6	35
33	Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. <i>Haemophilia</i> , 2013, 19, 481-486.	2.1	16
34	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. <i>Blood</i> , 2012, 120, 2405-2411.	1.4	160
35	Viscosupplementation in haemophilic arthropathy: a longâ€term followâ€up study. <i>Haemophilia</i> , 2012, 18, e210-4.	2.1	26
36	Pharmacokinetic properties of <sc>IB</sc>1001, an investigational recombinant factor <sc>IX</sc>, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. <i>Haemophilia</i> , 2012, 18, 881-887.	2.1	23

#	ARTICLE	IF	CITATIONS
37	Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. <i>Haemophilia</i> , 2011, 17, 854-859.	2.1	47
38	Inpatient rehabilitation in haemophilic subjects with total knee arthroplasty. <i>Haemophilia</i> , 2011, 17, e999-e1004.	2.1	11
39	Risk-sharing approach for managing factor VIIIa reimbursement in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2010, 16, 548-550.	2.1	3
40	Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. <i>Haemophilia</i> , 2009, 15, 983-989.	2.1	35
41	Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. <i>Blood</i> , 2009, 114, 779-784.	1.4	108
42	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. <i>Haematologica</i> , 2008, 93, 722-728.	3.5	95
43	ReFacto®1 and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. <i>Haemophilia</i> , 2007, 13, 124-130.	2.1	49
44	European Study on Orthopaedic Status of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2007, 13, 606-612.	2.1	192
45	A modular total knee arthroplasty in haemophilic arthropathy. <i>Knee</i> , 2007, 14, 264-268.	1.6	33
46	Accuracy of FVIII:C assay by one-stage method can be improved using hemophilic plasma as diluent. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 828-833.	3.8	21
47	Pharmacokinetic studies: international guidelines for the conduct and interpretation of such studies. <i>Haemophilia</i> , 2006, 12, 6-11.	2.1	12
48	Pharmacokinetics of factor VIII and factor IX. <i>Haemophilia</i> , 2003, 9, 94-100.	2.1	37
49	TT virus contaminates first-generation recombinant factor VIII concentrates. <i>Blood</i> , 2001, 98, 2571-2573.	1.4	39
50	Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. <i>Transfusion</i> , 1997, 37, 517-522.	1.6	96
51	Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia. <i>Transfusion</i> , 1993, 33, 814-818.	1.6	31
52	Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate. <i>Journal of Medical Virology</i> , 1992, 36, 71-74.	5.0	16
53	Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. <i>American Journal of Hematology</i> , 1992, 39, 228-230.	4.1	166
54	In vitro characteristics of highly purified factor VIII concentrates. <i>Annals of Hematology</i> , 1991, 63, 123-125.	1.8	4

#	ARTICLE	IF	CITATIONS
55	The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX. <i>Thrombosis and Haemostasis</i> , 1991, 66, 384-386.	3.4	90
56	The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 1991, 66, 384-6.	3.4	25
57	Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. <i>Journal of Medical Virology</i> , 1988, 25, 165-170.	5.0	109
58	Single-dose pharmacokinetics of Factor IX evaluated by model-independent methods. <i>European Journal of Haematology</i> , 1987, 39, 426-433.	2.2	21
59	Hepatitis-Free Interval After Clotting Factor Therapy in First Infused Haemophiliacs. <i>Thrombosis and Haemostasis</i> , 1986, 56, 268-270.	3.4	14
60	Hepatitis-free interval after clotting factor therapy in first infused haemophiliacs. <i>Thrombosis and Haemostasis</i> , 1986, 56, 268-70.	3.4	2
61	Evaluation of Prophylactic Replacement Therapy in Haemophilia B. <i>Scandinavian Journal of Haematology</i> , 1976, 16, 41-47.	0.0	36